On July 27, the Indonesia-China Healthcare and Biotechnology Investment Forum, co-sponsored by the Embassy of the Republic of Indonesia in China and the China Committee of the Indonesian Chamber of Commerce and Industry, was held in Chengdu.
Indonesia's Health Minister Budi Gunadi Sadikin, Indonesia's Ambassador to China Zhou Hao Li, and Indonesian Chamber of Commerce and Industry Chairman Arsjad Rasjid attended and witnessed the signing of a strategic cooperation agreement between Wondfo Biotech and Indonesian pharmaceutical company Kimia Farma (KAEF), which will work together to improve the healthcare quality for the Indonesian people in the field of in-vitro diagnostics.
KAEF is the first pharmaceutical company established in Indonesia and its main business areas include R&D-supported pharmaceutical manufacturing, distribution and trading, pharmaceutical sales, pharmaceutical retailing, testing laboratories and clinics. 20 In February 2023, the Silk Road Fund (SRF), a medium- to long-term development institution set up by China to support the construction of the "One Belt, One Road" initiative, and the Indonesian Investment Authority (INA) announced the successful closing of a joint investment project in KAEF and its subsidiary Kimia Farma Apotek (KFA).
In February 2023, the Silk Road Fund (SRF), a medium- to long-term development institution set up by China to support the construction of the "Belt and Road", and the Indonesia Investment Authority (INA) announced the successful closing of a joint investment project in KAEF and its subsidiary Kimia Farma Apotek (KFA), marking a milestone in the cooperation between China and Indonesia under the "Belt and Road" Initiative.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.